Non Hodgkin Lymphoma Clinical Trial
Phase 1a/1b Study of IGM-8444 Alone and in Combination in Subjects With Relapsed, Refractory, or Newly Diagnosed Cancers
This study is a first-in-human, Phase 1, multicenter, open-label study to determine the safety, tolerability and pharmacokinetics of IGM-8444 as a single agent and in combination in subjects with relapsed and/or refractory solid or hematologic cancers, as well as newly diagnosed cancers
Patients will be enrolled in Phase 1a, which consists of two stages: a dose-escalation stage and an expansion stage. IGM-8444 will be used as a single agent and in combination with numerous other agents where standard therapeutic regimens do not exist, have proven to be ineffective or intolerable, or are considered inappropriate.
Colorectal patients may be enrolled in Phase 1b, an open-label, randomized study of IGM-8444+FOLFIRI (± bevacizumab)
IGM-8444 will be investigated in numerous tumor types including all-comers solid tumors, colorectal carcinoma (CRC), sarcoma, non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL).
IGM-8444 will be administered intravenously (IV).
An alternative dosing schedule may be evaluated.
Key Inclusion Criteria:
Age ≥ 18 years at time of signing ICF
ECOG Performance Status of 0 or 1
Histologic documentation of incurable, locally advanced or metastatic tumor of the type being evaluated in individual cohorts.
Adequate hepatic and renal function and adequate bone marrow reserve function.
For combination cohorts, patients must be eligible to receive the chemotherapy or targeted agent.
Ph1a only: No more than three prior therapeutic regimens.
Ph1b only: Must be FOLFIRI naive subjects and must have received only 1 prior therapeutic regimen administered for the treatment of cancer in the advanced/metastatic setting.
Key Exclusion Criteria:
Inability to comply with study and follow-up procedures.
Prior DR5 agonist therapy.
Concomitant use of agents well-known to cause liver toxicity.
Concomitant use of anti-cancer agents
Palliative radiation to bone metastases within 2 weeks prior to Day 1.
Major surgical procedure within 4 weeks prior to Day 1.
Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control). Patients with a history of treated CNS metastases are eligible.
Prior use of any chemotherapeutic agent or small molecule inhibitors (SMI) within 2 weeks or 5 half-lives, prior to the first dose of study treatment
Treatment with a monoclonal antibody, or any other anticancer agent (including biologic, experimental, or hormonal therapy) investigational or otherwise, that is not chemotherapy or a SMI, within 4 weeks or five half-lives prior to first dose of study treatment.
Ph1b: Subjects who have previously received FOLFIRI treatment for advanced or metastatic disease
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 32 Locations for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.